Skip to main content
RGEN
NASDAQ Life Sciences

Repligen Closes $1.0B 0.25% Convertible Notes Due 2031, Refinancing Most of Its 2028 Notes

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Medical Instrument Stocks · Healthcare
Sentiment info
Neutral
Importance info
7
Price
$173.49
Mkt Cap
$11.09B
52W Low
$100.99
52W High
$198.87
52W Position info
72% above low
Off High info
13% below high
Rel. Volume info
0.9× avg
Market data snapshot near publication time

RGEN sits 72% above its 52-week low of $100.99.

Summary

Repligen closed its $1.0 billion 0.25% convertible notes due 2031, using about $541.4 million to exchange and cancel old 1.00% 2028 notes and selling about $458.6 million for cash. Conversion is at roughly $226.37 a share, with up to 5,301,100 shares issuable.


Key Events · Financing and Capital Events · RGEN

  • $1.0B Convertible Notes Issued

    Repligen issued $1.0 billion of 0.25% Convertible Senior Notes due 2031 under an Indenture dated November 6, 2026, with interest payable semi-annually starting May 1, 2027.

  • Old 2028 Notes Mostly Retired

    About $541.4 million of new notes were exchanged for about $456.8 million principal of 1.00% 2028 notes, which were canceled; about $143.2 million of 2028 notes remains outstanding on unchanged terms.

  • Cash Subscription Leg

    About $458.6 million principal of new notes was sold for about $458.6 million in cash to institutional accredited investors and qualified institutional buyers under Section 4(a)(2).

  • Conversion at ~$226.37, 20% Premium

    The initial conversion rate is 4.4176 shares per $1,000, equivalent to about $226.37 per share, a roughly 20% premium to the $188.64 close on October 29, 2026; up to 5,301,100 shares may initially be issued on conversion.


Analysis · RGEN · Life Sciences

The story here is the final terms: Repligen has now actually issued the $1.0 billion of 0.25% convertible notes it announced on October 30. Roughly $541.4 million of the new notes went to holders exchanging about $456.8 million of the old 1.00% 2028 notes, which were canceled, and about $458.6 million was sold for cash. That swaps high-coupon debt for near-zero-coupon debt and pushes maturity out to 2031, a real interest-cost saving, while leaving only about $143.2 million of the 2028 notes outstanding. The cost is potential dilution: the notes convert at about $226.37 a share, roughly 20% above the $188.64 close on October 29, and up to 5,301,100 shares could be issued on conversion. That is a manageable overhang against the current share count, and the premium means holders only get shares if the stock rises well above today's $173.49. The cash raised funds the exchange and general corporate needs, including the pending BioLife acquisition financing picture.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, RGEN was trading at $173.49 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $11.1B. The 52-week trading range was $100.99 to $198.87. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

RGEN - Latest Insights

RGEN
Oct 30, 2026, 4:01 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $176.94
Real-time Price: $163.81 info
Change: -$13.13 (-7%) info
Market Cap: $10.471B info
RGEN
Oct 30, 2026, 6:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $188.64
Real-time Price: $163.81 info
Change: -$24.83 (-13%) info
Market Cap: $10.471B info
RGEN
Oct 27, 2026, 7:04 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $181.38
Real-time Price: $163.81 info
Change: -$17.57 (-10%) info
Market Cap: $10.471B info
RGEN
Oct 27, 2026, 7:00 AM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $181.38
Real-time Price: $163.81 info
Change: -$17.57 (-10%) info
Market Cap: $10.471B info
RGEN
Sep 08, 2026, 5:26 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $168.53
Real-time Price: $163.81 info
Change: -$4.72 (-3%) info
Market Cap: $10.471B info